ClinicalTrials.gg
CompletedNCT03394027Updated Aug 23, 2022Results posted

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

A Phase 2 interventional study of ONC201 in Triple Negative Breast Cancer, Endometrial Cancer and Hormone Receptor Positive, HER2 Negative Breast Cancer, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-23.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 45 studies in Triple Negative Breast Neoplasms by National Cancer Institute (NCI) — 6 open to participants now, 16 under way, 1 of them phase 3. Triple Negative Breast Neoplasms · National Cancer Institute (NCI).

Enrollment
27th of 43
30 · median 37
Started
2018
with 2 others
Phase 2
12 of 45
1 open now
Registered
30th of 45
by date

Among the 45 studies in Triple Negative Breast Neoplasms by National Cancer Institute (NCI), this one is the 27th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2018, is one of 12 in phase 2, and was the 30th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 443 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

6 of the 45 studies in Triple Negative Breast Neoplasms by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 330 Triple Negative Breast Neoplasms studies recruiting now, 230 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Triple Negative Breast Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

The new drug ONC201 have been shown to kill breast cancer and endometrial cancer cells in the laboratory. The exact mechanism of action is not completely clear yet, but the ONC201 destroys the mitochondria inside the cells. Blocking mitochondrial activity may kill tumor cells, which would shrink tumors. Researchers want to see if ONC201 helps shrink tumors of certain breast or endometrial cancers and if that effect is maintained.

Objective:

To see if ONC201 shrinks tumors with a lasting effect.

Eligibility:

Adults ages 18 and older who have metastatic breast cancer (hormone-positive or triple-negative) or metastatic endometrial cancers.

Design:

Participants will be screened with:

  • Medical history
  • Physical exam
  • Heart, blood, and urine tests
  • Computed tomography (CT) and bone scans
  • Review of medical report and tumor sample
  • Participants will have a tumor biopsy before starting treatment and after 5 weeks taking the study drug. A scan or ultrasound may be used to guide the biopsy. Patients will receive local anesthetic and a needle will remove a small piece of tumor.
  • The study will be done in 28-day cycles. Every day 1 of each cycle participants will repeat most screening tests, will be seen by the physician and receive a supply of the study drug.
  • Participants will take the study drug by mouth once every 7 days. They will keep a diary of when they take the drug and any side effects. During cycle 1, participants will get weekly calls to discuss their health and symptoms. Images will be repeated every 2 cycles to evaluate response to the treatment.
Read the detailed description

Background:

  • Advanced breast cancer and endometrial cancer have limited treatment options. Current treatments provide a modest improvement in progression free survival, but no treatments improve survival.
  • ONC201 is the founding member of a novel class of anticancer drugs called imipridones. The exact mechanism of ONC201 is unknown at this time, but preclinical data suggests that it causes global downregulation of mitochondrial genes leading to mitochondrial damage and ultimately non-apoptotic cell death.
  • Preclinical studies have demonstrated that ONC201 selectively kills various cancer cells, including breast cancer cells (hormone-receptor positive cell lines, human epidermal growth factor receptor 2 (HER2+) cell line as well as triple negative breast cancer cell lines) and endometrial cancer cells, while having little effect on normal cells.
  • An on-going phase I study of ONC201 has demonstrated clinical benefit in some solid tumors, including endometrial cancer.

Objectives:

  • Cohort 1: To determine the progression free survival (PFS) at 8 months of ONC201 in metastatic hormone receptor positive breast cancer (HR+BC)
  • Cohort 2: To determine the overall response rate (ORR) of ONC201 in metastatic triple negative breast cancer (TNBC)
  • Cohort 3: To determine the overall response rate (ORR) of ONC201 in advanced endometrial cancer (EC)

Eligibility:

Selected Inclusion Criteria

  • Histologically confirmed metastatic breast cancer or endometrial cancer with appropriate immunohistochemistry (IHC) testing and confirmation of HER2 non-amplification required for the breast cancer cohorts (cohorts 1 and 2)
  • Age 18 years or older
  • Female and male breast cancer patients are eligible for the breast cancer cohorts
  • Eastern Cooperative Oncology Group (ECOG) 0 or 1
  • Measurable metastatic disease with greater than or equal to 1 biopsiable lesion with willingness to undergo a biopsy
  • Cohort 1 Hormone receptor + breast cancer (HR+BC) requires prior treatment with greater than or equal to 2 lines of hormonal treatment. No prior treatment required for cohorts 2/3 (TNBC and EC).
  • Adequate hematopoietic, hepatic and renal function

Selected Exclusion Criteria

  • Patients who have received chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin); other investigational agents within 3 weeks or a programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PDL1) agent within 4 weeks prior to first dose of study treatment.
  • Radiotherapy less than or equal to 4 weeks before first dose of study treatment.
  • Symptomatic central nervous system (CNS) metastases. Asymptomatic or brain metastases treated greater than 4 weeks from first dose of study treatment are allowed.
  • History of invasive malignancy less than or equal to 3 years
  • Known history of cardiac arrhythmias including uncontrolled atrial fibrillation, tachyarrhythmias or bradycardia.
  • History of congestive heart failure (CHF), or myocardial infarction (MI) or stroke in the previous 3 months will be excluded.
  • Started denosumab or bisphosphonate therapy within 28 days prior to Cycle 1 Day 1
  • Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection

Design:

  • This is a phase II single arm study of ONC201 divided in three cohorts, each cohort with different type of metastatic, advanced disease:
  • Cohort 1: HR+ breast cancer (male and female)
  • Cohort 2: Triple negative breast cancer (male and female)
  • Cohort 3: Endometrial cancer (female only)
  • All patients will receive ONC201 at the recommended phase 2 dose (RP2D) of 625mg by mouth every 7 days with each cycle being 28 days long. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive
  • Patients will be evaluated for toxicity every 4 weeks by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and for response every two cycles (8 weeks) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
03

Conditions studied

  • Triple Negative Breast Cancer
  • Endometrial Cancer
  • Hormone Receptor Positive, HER2 Negative Breast Cancer

Keywords

  • Imipridones
  • TNBC
  • Metastatic
  • Male Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • INCLUSION CRITERIA FOR COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER:
  • Patients must have confirmed persistent or recurrent invasive hormone receptor positive, human epidermal growth factor receptor 2 () normal breast cancer for which standard curative measures do not exist or are no longer effective. Hormone receptor positive is defined as estrogen receptor (ER) positive greater than or equal to 10% by immunohistochemistry (IHC) and/or progesterone receptor (PR) positive greater than or equal to 10% by IHC.HER2 will be considered negative per American Society of Clinical Oncology (ASCO)-College of American Pathologists (CAP) guidelines (HER2 test result as negative if a single test (or both tests) performed show: 1) IHC 1+ as defined by incomplete membrane staining that is faint/barely perceptible and within >10% of the invasive tumor cells; 2) IHC 0 as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within less than or equal to 10% of the invasive tumor cells; or 3) ISH negative based on: a) Single-probe average HER2 copy number \<4.0 signals/cell or b) Dualprobe HER2/ chromosome enumeration probe 17 (CEP17) ratio \<2.0 with an average HER2 copy number \<4.0 signals/cell)and HER2 testing must have been performed in a laboratory accredited by the College of American Pathologists (CAP) or another accrediting entity.
  • Patients must have , per (RECIST) 1.1.
  • Patients must have at least one lesion deemed safe to and be willing to undergo mandatory biopsies.
  • Hormone receptor + breast cancer (HR+BC) patients must have received prior treatment with at least 2 lines of hormonal treatment (Selective estrogen receptor modulators (SERM), aromatase inhibitor (AI), or fulvestrant) and deemed ineligible for further hormonal therapy. Patients may have received prior chemotherapy and there is no limit to the number of prior chemotherapy.
  • Age greater than or equal to18 years.
  • (ECOG) performance status 0 or 1
  • Adequate renal function, defined as serum creatinine less than or equal to 1.5 X (ULN), or measured greater than or equal to 60 mL/min/1.
  • Adequate hepatic function, defined as (AST) and alanine aminotransferase (ALT) levels less than or equal to 3 X ULN and total \< 1.5 X ULN, unless known diagnosis of Gilbert's syndrome, where bilirubin less than or equal to 5 mg/dL will be permitted. Gilbert's syndrome will be defined as elevated unconjugated bilirubin, with conjugated (direct) bilirubin within the normal range and less than 20% of the total. Total bilirubin will be permitted up to 5 mg/dL, if patients have historical readings consistent with the definition of Gilbert's syndrome prior to entering study.
  • Adequate bone marrow function, defined as absolute neutrophil (ANC) greater than or equal to 1,500/mm\^3 (greater than or equal to 1.5 X10\^6/L), count greater than or equal to 75,000/mm\^3 (greater than or equal to 75 X10\^6/L), and greater than or equal to 9 mg/dL (transfusion to obtain hemoglobin greater than or equal to 9 mg/dL within 24 hours prior to dosing is allowed).
  • Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulation.
  • The effects of ONC201 on the developing human fetus are unknown. For this reason and because imipridone agents are known to be teratogenic, female patients must either be of non- (i.e., by history: greater than or equal to 60 years old and no menses for greater than or equal to 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry and agree to use or abstinence during the study and for and for at least 4 weeks after the final dose of any study-related medications. Male patients must use at least two forms of contraception during the study and for at least 4 weeks after the final dose of any study-related medications or have a partner who is not of reproductive potential.
  • Ability of subject to understand and the willingness to sign a written document.

EXCLUSION CRITERIA FOR COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER:

  • Patients who have received chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin); other agents within 3 weeks or a programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PDL1) agent within 4 weeks prior to first dose of study enrollment.
  • Patients who have undergone radiotherapy within 4 weeks of first dose of study treatment.
  • Patients with a history of another invasive within the last 3 years.
  • Patients with symptomatic or . Patients with asymptomatic or brain metastases that have been treated with radiation at least 4 weeks prior to first dose of study treatment are allowed.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study.
  • Patients with a mean corrected Q wave T wave () interval by Fridericia (QTcF) interval of > 500 msec or receiving therapeutic agents known to prolong the QT interval
  • Known history of cardiac arrhythmias including uncontrolled atrial fibrillation, tachyarrhythmias or bradycardia, history of congestive heart failure, or myocardial infarction or stroke in the previous 3 months will be excluded.
  • Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent.
  • Patients with bone metastases who have initiated denosumab or bisphosphonate therapy within 28 days prior to Cycle 1 Day 1.
  • Pregnant women are excluded from this study because ONC201 has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ONC201, breastfeeding should be discontinued if the mother is treated with ONC201. These potential risks may also apply to other agents used in this study.
  • (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ONC201.
  • Patients who have known active , or infections.

INCLUSION CRITERIA FOR COHORT 2: TRIPLE NEGATIVE BREAST CANCER:

  • Patients must have histologically or cytologically confirmed persistent or recurrent invasive, metastatic triple negative breast cancer (TNBC) for which standard curative measures do not exist or are no longer effective. TNBC, defined as estrogen receptor (ER) negative (ER \< 10%), PR negative (PR \<10%). HER2 will be considered negative per ASCO-CAP guidelines (HER2 test result as negative if a single test (or both tests) performed show: 1) IHC 1+ as defined by incomplete membrane staining that is faint/barely perceptible and within >10% of the invasive tumor cells; 2) IHC 0 as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within less than or equal to 10% of the invasive tumor cells; or 3) ISH negative based on: a) Single-probe average HER2 copy number \<4.0 signals/cell or b) Dual-probe HER2/CEP17 ratio \<2.0 with an average HER2 copy number \<4.0 signals/cell) and HER2 testing must have been performed in a laboratory accredited by the College of American Pathologists (CAP) or another accrediting entity.
  • Patients must have received at least one in the metastatic setting.
  • Patients must have measurable disease, per RECIST 1.1.
  • Patients must have at least one lesion deemed safe to biopsy and be willing to undergo mandatory biopsies.
  • Eligible patients may or may not have received prior chemotherapy and there is no limit to the number of prior chemotherapy. Patients are also eligible if they have received treatment with immunotherapy, such inhibitors, PD-L1 inhibitors or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors.
  • Age greater than or equal to 18 years.
  • ECOG performance status 0 or 1
  • Adequate renal function, defined as serum creatinine less than or equal to 1.5 X upper limit of normal (ULN), or measured creatinine clearance greater than or equal to 60 mL/min/1.
  • Adequate hepatic function, defined as AST and ALT levels less than or equal to 3 X ULN and total bilirubin \< 1.5 X ULN, unless known diagnosis of Gilbert's syndrome, where bilirubin less than or equal to 5 mg/dL will be permitted. Gilbert's syndrome will be defined as elevated unconjugated bilirubin, with conjugated (direct) bilirubin within the normal range and less than 20% of the total. Total bilirubin will be permitted up to 5 mg/dL, if patients have historical readings consistent with the definition of Gilbert's syndrome prior to entering study.
  • Adequate bone marrow function, defined as absolute neutrophil (ANC) greater than or equal to 1,500/mm\^3 (greater than or equal to 1.5 X10\^6/L), platelet count greater than or equal to 75,000/mm\^3 (greater than or equal to 75 X10\^6/L), and hemoglobin greater than or equal to 9 mg/dL (transfusion to obtain hemoglobin greater than or equal to 9 mg/dL within 24 hours prior to dosing is allowed)
  • Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulation.
  • The effects of ONC201 on the developing human fetus are unknown. For this reason and because imipridone agents as well as other therapeutic agents used in this trial are known to be teratogenic. Female patients must either be of non-reproductive potential (i.e., post-menopausal by history: greater than or equal to 60 years old and no menses for greater than or equal to 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry and agree to use contraception or abstinence during the study and for and for at least 4 weeks after the final dose of any study-related medications. Male patients must use at least two forms of contraception during the study and for and for at least 4 weeks after the final dose of any study-related medications or have a partner who is not of reproductive potential.
  • Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA FOR COHORT 2: TRIPLE NEGATIVE BREAST CANCER:

  • Patients who have received chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin); other investigational agents within 3 weeks or a PD1/PDL1 agent within 4 weeks prior to first dose of study treatment.
  • Patients who have undergone radiotherapy within 4 weeks of first dose of study treatment.
  • Patients with a history of another invasive malignancy within the last 3 years.
  • Patients with symptomatic brain metastases or leptomeningeal involvement. Patients with asymptomatic or brain metastases that have been treated with radiation at least 4 weeks prior to first dose of study treatment are allowed.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study.
  • Patients with a mean QTcF interval of > 500 msec or receiving therapeutic agents known to prolong the QT interval
  • Known history of cardiac arrhythmias including uncontrolled atrial fibrillation, tachyarrhythmias or bradycardia, history of congestive heart failure, or myocardial infarction or stroke in the previous 3 months will be excluded.
  • Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent
  • Patients with bone metastases who have initiated denosumab or bisphosphonate therapy within 28 days prior to Cycle 1 Day 1.
  • Pregnant women are excluded from this study because ONC201 has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ONC201, breastfeeding should be discontinued if the mother is treated with ONC201. These potential risks may also apply to other agents used in this study.
  • HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ONC201.
  • Patients who have known active Hepatitis B, or Hepatitis C infections.

INCLUSION CRITERIA FOR COHORT 3: ENDOMETRIAL CANCER:

  • Patients must have histologically or cytologically confirmed persistent or recurrent advanced or metastatic invasive endometrial cancer (EC) for which standard curative measures do not exist or are no longer effective.
  • Patients must have measurable disease, per RECIST 1.1
  • Patients must have at least one lesion deemed safe to biopsy and be willing to undergo mandatory biopsies.
  • Women with endometrial cancer must have had at least one prior line of therapy in the metastatic/recurrent setting but there is no limit to the number of prior chemotherapy lines. Patients are eligible if they have received treatment with immunotherapy, such PD-1 inhibitors, PD-L1 inhibitors or CTLA4 inhibitors.
  • Age greater than or equal to 18 years.
  • ECOG performance status 0 or 1
  • Adequate renal function, defined as serum creatinine less than or equal to 1.5 X upper limit of normal (ULN), or measured creatinine clearance greater than or equal to 60 mL/min/1.
  • Adequate hepatic function, defined as AST and ALT levels less than or equal to 3 X ULN and total bilirubin \< 1.5 X ULN, unless known diagnosis of Gilbert's syndrome, where bilirubin less than or equal to 5 mg/dl will be permitted. Gilbert's syndrome will be defined as elevated unconjugated bilirubin, with conjugated (direct) bilirubin within the normal range and less than 20% of the total. Total bilirubin will be permitted up to 5 mg/dL, if patients have historical readings consistent with...
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Arm 1-ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

    Single arm divided in three cohorts, each cohort with a different type of metastatic disease: estrogen receptor (ER) + breast cancer, triple negative breast cancer, and endometrial cancer

    Drug: ONC201

Interventions

  • DrugDordaviproneStudies of DordaviproneDordaviprone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.

06

What researchers measure

Primary outcomes

  1. Cohort 1 - Progression-free Survival (PFS)

    PFS in participants with refractory, metastatic hormone receptor positive breast cancer. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions. And the appearance of one or more new lesions.

    Time frame: Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).

  2. Cohort 2 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)

    Overall response (Complete response (CR) + Partial Response (PR) of ONC201 in participants with metastatic triple negative breast cancer was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions.

    Time frame: Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).

  3. Cohort 3 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)

    Overall response (Complete response (CR) + Partial Response (PR) of ONC201 in participants with advanced or metastatic endometrial cancer was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions.

    Time frame: Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).

Secondary outcomes

  1. Number of Serious and Non-serious Adverse Events Grade ≥1 in Cohorts 1, 2, and 3

    Serious and non-serious adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, , Grade 4 is life-threatening, and Grade 5 is death related to adverse event.

    Time frame: Date treatment consent signed to date off study, approximately 13 months and 28 days for cohort 1, 11 months and 12 days for cohort 2, and 34 months and 29 days for cohort 3.

  2. Cohort 1 - Overall Response Rate (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)

    Overall response (Complete response (CR) + Partial Response (PR) of ONC201 in participants with refractory, metastatic hormone receptor positive breast cancer was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions.

    Time frame: Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).

  3. Number of Participants in Cohorts 1, 2, and 3 With Clinical Benefit

    Clinical benefit is Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (i.e., at least a 20% increase in the sum of the diameters of target lesions).

    Time frame: Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).

  4. Cohorts 2 and 3 - Progression-free Survival (PFS)

    PFS in participants with triple negative breast cancer and endometrial cancer. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions. And the appearance of one or more new lesions.

    Time frame: Every 8 weeks, while on treatment, up to 3 months

Other outcomes

  1. Here is the Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).

    Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: Date treatment consent signed to date off study, approximately 13 months and 28 days for cohort 1, 11 months and 12 days for cohort 2, and 34 months and 29 days for cohort 3.

07

Results

Posted Jan 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneCohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)
Started10614
Completed7510
Not completed314
Withdrew: Ineligible313
Withdrew: Participant declined to participate before treatment started001

Outcome measures

PrimaryCohort 1 - Progression-free Survival (PFS)

PFS in participants with refractory, metastatic hormone receptor positive breast cancer. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions. And the appearance of one or more new lesions.

Time frame:
Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).
Reported as:
Median · Months
Cohort 1 - Progression-free Survival (PFS)
MonthsCohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)
Cohort 1 - Progression-free Survival (PFS)1.9 (0.6 to 4)
PrimaryCohort 2 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)

Overall response (Complete response (CR) + Partial Response (PR) of ONC201 in participants with metastatic triple negative breast cancer was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions.

Time frame:
Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).
Reported as:
Count of participants · Participants
Cohort 2 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)
ParticipantsCohort 2-Triple Negative Breast Cancer (Male and Female)
Complete Response0
Partial Response0
PrimaryCohort 3 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)

Overall response (Complete response (CR) + Partial Response (PR) of ONC201 in participants with advanced or metastatic endometrial cancer was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions.

Time frame:
Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).
Reported as:
Count of participants · Participants
Cohort 3 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)
ParticipantsCohort 3-Endometrial Cancer (Female Only)
Complete Response0
Partial Response0
SecondaryNumber of Serious and Non-serious Adverse Events Grade ≥1 in Cohorts 1, 2, and 3

Serious and non-serious adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, , Grade 4 is life-threatening, and Grade 5 is death related to adverse event.

Time frame:
Date treatment consent signed to date off study, approximately 13 months and 28 days for cohort 1, 11 months and 12 days for cohort 2, and 34 months and 29 days for cohort 3.
Reported as:
Number · Adverse events
Number of Serious and Non-serious Adverse Events Grade ≥1 in Cohorts 1, 2, and 3
Adverse eventsCohort 1 - Grade 1Cohort 1 - Grade 2Cohort 1 - Grade 3Cohort 1 - Grade 4Cohort 1 - Grade 5Cohort 2 - Grade 1Cohort 2 - Grade 2Cohort 2 - Grade 3Cohort 2 - Grade 4Cohort 2 - Grade 5Cohort 3 - Grade 1Cohort 3 - Grade 2Cohort 3 - Grade 3Cohort 3 - Grade 4Cohort 3 - Grade 5
Abdominal distension000001000000000
Abdominal pain000002000000000
*Abdominal pain010000100000000
Alanine aminotransferase increased201001100012000
Alkaline phosphatase increased021001110022000
Anemia200001530022000
*Anemia000001110000000
Anorexia410000000001000
Arthralgia000000000010000
Ascites010000000000000
Aspartate aminotransferase increased013100111031000
*Atrial flutter000000000000100
Back pain000000000001000
Blood bilirubin increased000001110000000
Breast pain000001100000000
*Breast pain000000010000000
*Cardiac arrest000000000000001
Confusion000001000000000
Constipation003001000010000
Cough100001000010000
Creatinine increased000001000002000
Dehydration100000000000000
*Dehydration000000000000100
Diarrhea200000000030000
*Diarrhea000000000001000
Dizziness100000000050000
*Dysarthria010000000000000
Dysgeusia100000000000000
Dyspepsia100000000000000
Dyspnea010000000011000
*Dyspnea000000010000000
Edema limbs100000000001000
Epistaxis100000000000000
Facial pain100000000000000
Fall100000000000000
*Fall001000000000000
Fatigue210001000052000
*Fatigue001000000000000
Fever300001000000000
*Fever000001000000000
Flu like symptoms010000000010000
Flushing000001000000000
Gastroesophageal reflux disease000000000010000
Headache000000000020000
Hot flashes000001000000000
Hyperhidrosis100001000000000
Hypermagnesemia100000010000000
Hypoalbuminemia010001110000000
Hypocalcemia000001000000000
Hypomagnesemia000002000000000
Hypophosphatemia000000000011000
Hypotension000001010000000
Insomnia000001000000000
Laryngeal hemorrhage100000000000000
Lethargy100000000010000
Lymphedema000000000010000
Lymphocyte count decreased221001100022200
Malaise100000000010000
Memory impairment000001000000000
Mucosal infection000000000001000
Myalgia100001000010000
Nausea310003000020000
*Nausea000000010000000
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify000010000000000
*Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify000010000100001
Nervous system disorders - Other, specify000001000000000
Non-cardiac chest pain100000000000000
Pain110000000000000
*Pain001000000000100
Pain in extremity010000000000000
Paresthesia000000000010000
*Peripheral sensory neuropathy010000000000000
Platelet count decreased100000000000000
Pleural effusion010000000001000
*Pleural effusion000000100000000
Proteinuria110000000010000
*Pneumonitis000000100000000
Pruritus100000000000000
Rash maculo-papular000000000010000
Rhinorrhea000000000010000
*Sepsis000000010000010
Sinus tachycardia000000100020000
*Sinus tachycardia000000000010000
*Stroke000000000000100
*Thromboembolic event000000000001100
*Transient ischemic attacks100000000000000
*Tremor010000000000000
*Tumor hemorrhage000000110000000
Upper respiratory infection010000000000000
Urinary tract infection001000000000000
*Urinary tract infection000000000000100
Vaginal discharge000000000010000
Vaginal hemorrhage000000000010000
Vascular access complication000000000000100
Vomiting300001000000000
*Vomiting000001000000000
Weight loss010000000010000
Wheezing100000000000000
White blood cell decreased100000000000000
SecondaryCohort 1 - Overall Response Rate (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)

Overall response (Complete response (CR) + Partial Response (PR) of ONC201 in participants with refractory, metastatic hormone receptor positive breast cancer was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions.

Time frame:
Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).
Reported as:
Count of participants · Participants
Cohort 1 - Overall Response Rate (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)
ParticipantsCohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)
Complete Response0
Partial Response0
SecondaryNumber of Participants in Cohorts 1, 2, and 3 With Clinical Benefit

Clinical benefit is Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (i.e., at least a 20% increase in the sum of the diameters of target lesions).

Time frame:
Every 8 weeks, while on the Trial. Participants were followed for an average of 8-10 weeks (up to 16 weeks).
Reported as:
Count of participants · Participants
Number of Participants in Cohorts 1, 2, and 3 With Clinical Benefit
ParticipantsCohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)
Complete Response000
Partial Response000
Stable Disease112
SecondaryCohorts 2 and 3 - Progression-free Survival (PFS)

PFS in participants with triple negative breast cancer and endometrial cancer. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the diameters of target lesions. And the appearance of one or more new lesions.

Time frame:
Every 8 weeks, while on treatment, up to 3 months
Reported as:
Median · Months
Cohorts 2 and 3 - Progression-free Survival (PFS)
MonthsCohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)
Cohorts 2 and 3 - Progression-free Survival (PFS)1.2 (0.5 to 1.8)2 (0.6 to 3)
Other pre-specifiedHere is the Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
Date treatment consent signed to date off study, approximately 13 months and 28 days for cohort 1, 11 months and 12 days for cohort 2, and 34 months and 29 days for cohort 3.
Reported as:
Count of participants · Participants
Here is the Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).
ParticipantsCohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)
Here is the Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).7510

Adverse events

Collected over Date treatment consent signed to date off study, approximately 13 months and 28 days for cohort 1, 11 months and 12 days for cohort 2, and 34 months and 29 days for cohort 3.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)2/7 (28.6%)4/7 (57.1%)7/7 (100%)
Cohort 2-Triple Negative Breast Cancer (Male and Female)1/5 (20%)3/5 (60%)5/5 (100%)
Cohort 3-Endometrial Cancer (Female Only)2/10 (20%)5/10 (50%)10/10 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventCohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)
Abdominal painGastrointestinal disorders1/71/50/10
AnemiaBlood and lymphatic system disorders0/71/50/10
Breast painReproductive system and breast disorders0/71/50/10
DyspneaRespiratory, thoracic and mediastinal disorders0/71/50/10
FeverGeneral disorders0/71/50/10
NauseaGastrointestinal disorders0/71/50/10
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, DeathNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/71/51/10
Pleural effusionRespiratory, thoracic and mediastinal disorders0/71/50/10
PneumonitisRespiratory, thoracic and mediastinal disorders0/71/50/10
SepsisInfections and infestations0/71/51/10
Most frequent other events
Showing 10 of 72
Most frequent other events
EventCohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)
AnemiaBlood and lymphatic system disorders2/73/52/10
FatigueGeneral disorders3/71/56/10
AnorexiaMetabolism and nutrition disorders4/70/51/10
Aspartate aminotransferase increasedInvestigations4/71/54/10
Alanine aminotransferase increasedInvestigations3/71/53/10
ConstipationGastrointestinal disorders3/71/51/10
Lymphocyte count decreasedInvestigations3/71/54/10
NauseaGastrointestinal disorders3/72/52/10
VomitingGastrointestinal disorders3/71/50/10
Abdominal painGastrointestinal disorders0/72/52/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)Total
<=18 years0000
Between 18 and 65 years86822
>=65 years2068
Age, Continuous
Age, Continuous(years)Cohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)Total
Mean60.14 ± 6.2553.88 ± 8.3763.65 ± 8.9960.53 ± 8.62
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)Total
Female1061430
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)Total
Hispanic or Latino1001
Not Hispanic or Latino851326
Unknown or Not Reported1113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)Total
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0101
Black or African American1326
White821121
More than one race0000
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(participants)Cohort 1-Hormone Receptor (HR) + Breast Cancer (Male and Female)Cohort 2-Triple Negative Breast Cancer (Male and Female)Cohort 3-Endometrial Cancer (Female Only)Total
United States1061430
08

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Greer YE, Lipkowitz S. TIC10/ONC201: a bend in the road to clinical development. Oncoscience. 2015 Feb 20;2(2):75-6. doi: 10.18632/oncoscience.133. eCollection 2015. No abstract available. PubMed 25859547 ↗
  • Endo Greer Y, Lipkowitz S. ONC201: Stressing tumors to death. Sci Signal. 2016 Feb 16;9(415):fs1. doi: 10.1126/scisignal.aad7955. PubMed 26884598 ↗
  • Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM. First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017 Aug 1;23(15):4163-4169. doi: 10.1158/1078-0432.CCR-16-2658. Epub 2017 Mar 22. PubMed 28331050 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to database of Genotypes and Phenotypes (dbGaP).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.

Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Mar 2021, 38 months.

Results were first posted in Jan 2022, 9 months after primary completion.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's 38 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2018
First posted
Jan 9, 2018
StartActual
Jan 17, 2018
Primary completionActual
Mar 18, 2021
CompletionActual
Oct 7, 2021
Results first posted
Jan 12, 2022
Last update
Aug 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03394027
Responsible party
Stanley Lipkowitz, MD, PhD (Principal Investigator, National Cancer Institute (NCI)) — Principal investigator
First posted
Jan 9, 2018
Start date
Jan 17, 2018
Primary completion
Mar 18, 2021
Completion
Oct 7, 2021
Results posted
Jan 12, 2022
Last update
Aug 23, 2022

Study contacts

Stanley Lipkowitz, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dordaviprone

Start the discussion